<DOC>
	<DOCNO>NCT02697032</DOCNO>
	<brief_summary>Rationale : The purpose evaluate whether non-invasive vivo image androgen receptor ( AR ) presence metastatic breast cancer patient mean 18F-fluoro-dihydrotestosterone positron emission tomography ( FDHT-PET ) use predict ( early ) treatment response , optimal dosing , anti androgen bicalutamide . The ultimate goal contribute optimal selection breast cancer patient anti androgen treatment . Objective : Feasibility detect diffrence uptake 18F-FDHT scan 6 week treatment bicalutamide metastatic breast cancer patient . Secondary Objectives : describe whether change 18F-FDHT tracer uptake six week associate response bicalutamide , describe whether change AR availability different breast cancer subgroup treatment bicalutamide describe whether 18F-FDHT tracer uptake influenced amount AR tumor expression . Study design : This single arm , one stage feasibility study , execute University Medical Center Groningen , The Netherlands . The primary endpoint study evaluate difference 18F-FDHT uptake tumor lesion 6 week bicalutamide treatment patient AR-positive metastatic breast cancer . Patients treat bicalutamide progression unacceptable toxicity encounter . Study population : The investigator include 20 postmenopausal metastatic breast cancer patient AR positive , HER2 negative tumor . Patients restaged clinically bone scintigraphy CT scan within 6 week timeframe PET examination . Intervention : All patient receive baseline FDHT-PET scan start bicalutamide treatment 150mg daily . During follow-up patient receive one FDHT-PET scan 6 week . Treatment bicalutamide continue progression unacceptable toxicity encounter . Main study endpoint : The percent difference 18F-FDHT uptake tumor lesion 6 week monotherapy bicalutamide . A minimum decrease 20 % 18F-FDHT uptake 6 week compare baseline uptake α 0.05 power 80 % , consider clinical significant .</brief_summary>
	<brief_title>FDHT PET Bicalutamide Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>1 . A history histological proven ARpositive ( i.e . &gt; 10 % staining ) , HER2negative metastatic breast cancer ( preferably assessment fresh metastasis biopsy , alternatively archival metastasis biopsy ) 2 . Tumor progression least one line systemic treatment 3 . Measurable disease accord RECIST 1.1 ; evaluable disease 4 . Age ≥ 18 year 5 . Postmenopausal status define one following : Age ≥60 year Previous bilateral oophorectomy Age &lt; 60 year amenorrhea &gt; 12 month absence interfere hormonal therapy ( LHRH agonists ERantagonists Age &lt; 60 year use ER antagonist amenorrhea &gt; 12 month FSH &gt; 24U/L LH &gt; 14U/L 6 . Adequate hematological , renal liver function follow : Absolute neutrophil count &gt; 1.5 x 109/L Platelet count &gt; 100 x 109/L White blood cell count &gt; 3 x 109/L AST ALT &lt; 3.0 x upper limit normal ( ULN ) Alkaline phosphatase &lt; 2.5 x ULN Creatinine clearance &gt; 50mL/min Lipase/amylase &lt; 1/5 x ULN Protrombin time , partial tromboplastin time INR &lt; 1.5 x ULN 7 . Written inform consent 1 . Unable comply protocol 2 . Evidence central nervous metastasis 3 . Presence lifethreatening visceral metastasis 4 . Corrected QT interval ( QTc ) &gt; 500millliseconds screen 5 . Recent history cardiac disease , include myocardial infarction , unstable angina pectoris uncontrolled arrhythmia within 6 month prior screen ; evidence severe congestive heart failure New York Heart Association severity classification &gt; class I . 6 . Recent history tromboembolic event within 6 month prior screen 7 . Hepatic impairment ( ChildPugh Class B C ) 8 . Severe concurrent disease , infection , co morbid condition , judgment investigator would make patient inappropriate enrollment 9 . The concomitant use strong CYP3A4 inhibitor ( see table 1 ) 10 . Previous antiandrogen treatment 11 . Concurrent use ERdirected anti hormonal therapy 12 . Radiotherapy major surgery within 4 week baseline PET scanning</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>FDHT</keyword>
	<keyword>PET</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Bicalutamide</keyword>
</DOC>